Dr. Terry Snutch receives 2025 CLEAR funding to help advance dementia research

Congratulations to Dr. Terry Snutch on receiving a 2025 Operating Grant from CLEAR (Canadians for Leading Edge Alzheimer Research) to support his work in advancing dementia research.

Learn more about the research project:

Proof-of-concept of a stage 3 drug to attenuate hyper excitability-mediated pathophysiologies linked to Frontotemporal Dementia

Dr. Snutch’s ground-breaking translational research focuses on Frontotemporal Dementia (FTD), a devastating neurodegenerative disease. Employing animal models, his research aims to test the effectiveness of Z944, a Stage 3 drug that his lab designed to address hyperexcitability in neurons, a feature linked to FTD dementia progression. If successful, this research could potentially pave the way for a promising therapeutic option for FTD patients within just 2-3 years.

Visit the CLEAR website to learn about other research projects that have been funded by CLEAR in recent years.

 

A version of this article was originally posted on the Djavad Mowafaghian Centre for Brain Health (DMCBH) website. Dr. Snutch is one of two DMCBH researchers to receive CLEAR funding in 2025.